Supplement Aims and Scope
=========================

This supplement is intended to focus on tyrosine kinases in cancer. Aberrant tyrosine kinases and disease are included within the supplement's scope.

*Biomarker Insights* aims to provide researchers working in this complex, quickly developing field with online, open access to highly relevant scholarly articles by leading international researchers. In a field where the literature is ever-expanding, researchers increasingly need access to up-to-date, high quality scholarly articles on areas of specific contemporary interest. This supplement aims to address this by presenting high-quality articles that allow readers to distinguish the signal from the noise. The editor in chief hopes that through this effort, practitioners and researchers will be aided in finding answers to some of the most complex and pressing issues of our time.

Articles should focus on tyrosine kinases in cancer and may include the following topics: ■ Tyrosine kinases.Includes both tyrosine kinases and receptor tyrosine kinases, roles, including extracellular and intracellular signaling cascades.■ Aberrant tyrosine kinasesAbnormalities including point mutations, chromosomal translocations and downstream effects of constitutive activation.■ DiseaseRoles in cancer, including solid and haematological malignancies, the use of tyrosine kinase inhibitors (TKIs) and resistance to TKIs.

Tyrosine kinases are enzymes that are responsible for catalytic transfers the phosphate to amino acid residues in a protein, resulting in a conformational change affecting protein function. TKs as a key mediator of the signaling cascadesplay a significant role in various normal cellular regulatory processes such as growth, differentiation, apoptosis metabolism, adhesion, motility and death of cells. Recent advances have implicated the role of TK in the pathophysiology of cancer. Due to genetic aberrations like mutations and overexpression, they may acquire transforming functions leading to malignancy. The introduction of tyrosine kinase inhibitors (TKI) in the treatment of hematological malignancy has significantly increased survival of patients. Despite this advance, there are some controversial opinions concerning the treatment strategy in patients with refractory disease.

The supplement aims to present the role of aberrations in TK in haematological malignancies. The articles should be focused on the significance of TK aberrations in pathogenesis of acute and chronic myeloid leukemia. Also the role of TKI in the therapy of myeloid leukemia patients, in particular, in those with resistance to drugs will be present in case reports. Furthermore, the role of TKI in treatment of patients with indolent lymphatic neoplasia will be discussed. We hope that this supplement would be beneficial for medical doctors, researchers and practitioners.

Lead Guest Editor **Dr. Olga Blau**
===================================

**Dr. Olga Blau is research associate in molecular genetics in the hematological department at Charité University, Berlin.** She completed her PhD at the Saint-Petersburg State Pavlov Medical University and has previously worked at Saint-Petersburg State Pavlov Medical University. She now works primarily in field of scientific investigation of bone marrow stroma cells, genetics analysis of acute leukemia and multiple myeloma, and molecular monitoring after high dose therapy and stem cell transplantation. Dr. Blau is the author or co-author of 35 published papers and has presented at 20 conferences.
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Guest Editors
-------------

### BORIS AFANASYEV

Prof. Boris Afanasyev is a head of R.M. Gorbacheva Memorial Institute for Paediatric Oncology, Haematology and Transplantation at the First Pavlov State Medical University of St. Petersburg. He completed his PhD at the First State Pavlov Medical University of St. Petersburg and has previously worked at Institute of Oncology, Russia. He now works primarily in field of haematology and stem cell transplantation. Prof. Afanasyev is the author or co-author of 156 published papers and has presented at 120 conferences. Prof. Afanasyev holds editorial appointments at "Cell Therapy and Transplantation", "Oncohematology", "Pediatric Haematology/Oncology and Immunopathology", and "Hematology and Transfusiology".
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### IGOR WOLFGANG BLAU

Dr. Igor Wolfgang Blau is a head of the Bone Marrow Transplantation Department in the Clinic of Haematology, Oncology and Tumorimmunology at the Charité University, Berlin. He completed his PhD at the Charité University, Berlin and has previously worked at the Humboldt University, Berlin. He now works primarily in the field of scientific investigations of multiple myeloma patients and stem cell transplantation. Dr. Blau is the author or co-author more than 100 published papers and has presented at 80 conferences.
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